×
About 3,350 results

ALLMedicine™ Ewing Sarcoma Center

Research & Reviews  1,174 results

Cancer stem cells and chemoresistance in Ewing sarcoma.
https://doi.org/10.2174/1574888X17666220627114710
Current Stem Cell Research & Therapy; Dos Santos RP, Gregianin L et. al.

Jun 29th, 2022 - Resistance to chemotherapy poses a major challenge for cancer treatment. Reactivation of a stem cell program resembling that seen in embryonic development can lead cancer cells to acquire a stem-cell phenotype characterized by expression of stemne...

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT01804634

Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04890093

Jun 24th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...

Acetylation dependent translocation of EWSR1 regulates CHK2 alternative splicing in res...
https://doi.org/10.1038/s41388-022-02383-x 10.1038/s41572-018-0003-x 10.1038/359162a0 10.1093/nar/gki270 10.1128/MCB.18.3.1489 10.1172/JCI31222 10.1016/j.molcel.2007.11.015 10.1056/NEJMra0804615 10.1006/cimm.1995.1185 10.1016/S0092-8674(00)80086-0 10.1101/gad.1934210 10.1016/j.molcel.2011.05.035 10.1002/em.22397 10.1093/jmcb/mju045 10.1016/j.tibs.2009.12.003 10.1042/EBC20190095 10.1101/gad.2021311 10.1074/jbc.272.43.27369 10.1073/pnas.96.25.14300 10.1016/S0014-5793(00)01590-8 10.1046/j.1365-3083.1997.d01-447.x 10.1042/BJ20082097 10.1016/j.bbrc.2005.02.018 10.1111/j.1742-4658.2011.08020.x 10.1038/onc.2008.484 10.1126/science.8036511 10.1155/2013/642853 10.1016/j.jmb.2004.04.078 10.1074/jbc.M001661200 10.1038/nature00947 10.1016/j.cell.2005.01.028 10.1016/j.jid.2018.05.015 10.1007/s13238-011-1063-9 10.1128/MCB.01382-07 10.1007/s00018-017-2717-4 10.1074/jbc.M210479200 10.1074/jbc.M709707200 10.1128/MCB.01969-08 10.1016/j.febslet.2013.01.035 10.1016/j.cell.2009.03.010 10.1038/nsmb.1912 10.1038/35071124 10.1016/j.bbamcr.2010.01.005 10.1038/sj.onc.1207928 10.1038/s41419-020-2640-8 10.3389/fendo.2021.600682 10.1126/sciadv.abj8357 10.1146/annurev-biochem-060614-034325 10.1038/emboj.2011.106
Oncogene Zhang T, Wang Z et. al.

Jun 23rd, 2022 - Ewing sarcoma breakpoint region 1 (EWSR1) is a member of FET (FUS/EWSR1/TAF15) RNA-binding family of proteins. The Ewing sarcoma oncoprotein EWS-FLI1 has been extensively studied, while much less is known about EWSR1 itself, especially the potenti...

CIC-DUX4 sarcomas.
https://doi.org/10.1097/CCO.0000000000000855
Current Opinion in Oncology; Brahmi M, Vanacker H et. al.

Jun 23rd, 2022 - CIC-DUX4 sarcoma (CDS) is a high-grade undifferentiated round cells sarcoma that belongs to the undifferentiated round cell sarcomas family. It represents less than one percent of sarcomas, defining a rarest among rare malignancies. It affects you...

see more →

Guidelines  5 results

Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Li...
https://doi.org/10.1016/j.otsr.2018.12.015
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.

Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...

Practical recommendations for fertility preservation in women by the FertiPROTEKT netwo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762797
Archives of Gynecology and Obstetrics; Schüring AN, Fehm T et. al.

Nov 28th, 2017 - Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice. A selective ...

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.
https://doi.org/10.1093/annonc/mdu153
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.

Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the ...
https://doi.org/10.1002/pbc.21596
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.

May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...

Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq?cid=eb_govdel
National Cancer Institute

Dramatic improvements in survival have been achieved for children and adolescents with cancer.[1] Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[1] For Ewing sarcoma, the 5-year survival rate has increased from 59% t...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  95 results

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT01804634

Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04890093

Jun 24th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02657005

Jun 22nd, 2022 - The study has been expanded to explore single agent TK216 for longer treatment duration. Approximately 26 patients will be enrolled in this Cohort.

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT05071209

Jun 10th, 2022 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BAY 1895344 (elimusertib) administered as an oral tablet, twice per day for 3 days on and 4 days off to patients < 18 years of age with r...

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04901702

Jun 9th, 2022 - ONITT (ONIvyde, Talazoparib, Temozolomide) is a phase I/II study which will evaluate two treatment regimens; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL) and Onivyde (ONI) plus temozolomide (TMZ) for the treatment of recurren...

see more →

News  51 results

International Trial Finds Best Regimen for Ewing Sarcoma
https://www.medscape.com/viewarticle/975065

Jun 5th, 2022 - High-dose ifosfamide has shown superior survival benefit over three other chemotherapy regimens for patients with recurring or refractory primary Ewing sarcoma (RR-ES) in the practice-changing rEECur trial. This international trial is the first ra...

Devimistat Plus Hydroxychloroquine Shows Early Promise in Relapsed Clear Cell Sarcoma
https://www.onclive.com/view/devimistat-plus-hydroxychloroquine-shows-early-promise-in-relapsed-clear-cell-sarcoma

Jan 7th, 2022 - No dose-limiting toxicities (DLTs) have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat (CPI-613) and hydroxychloroquine in the dose-escalation portion of the ongoing phase ...

ONCT-216 Shows Encouraging Efficacy, Safety in Relapsed/Refractory Ewing Sarcoma
https://www.onclive.com/view/onct-216-shows-encouraging-efficacy-safety-in-relapsed-refractory-ewing-sarcoma

Nov 24th, 2021 - The targeted small molecule inhibitor of the E26 transformation-specific family of oncoproteins, ONCT-216 (formerly TK216), produced notable response and disease control rates when delivered at the recommended phase 2 dose (RP2D) to heavily pretre...

Demetri's Team Approach Translates Into Success in Sarcoma Research
https://www.onclive.com/view/demetris-team-approach-translates-into-success-in-sarcoma-research

Oct 6th, 2021 - George D. Demetri, MD For some cancer researchers, success means running your own laboratory independent of others, who might be viewed as competitors. Others, like George D. Demetri, MD, find success pursuing a career as a translational and clin...

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma
https://www.onclive.com/view/dr-federman-on-ongoing-research-in-rare-bone-and-soft-tissue-sarcoma

Oct 6th, 2021 - Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma. Current research at UCLA’s Jonnson Comprehensive Cancer Ce...

see more →

Patient Education  7 results see all →